Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.

Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, Barry WT, Dressman HK, Ginsburg GS, Marcom KP, Garman KS, Lyman GH, Nevins JR, Potti A.

JAMA. 2008 Apr 2;299(13):1574-87. doi: 10.1001/jama.299.13.1574. Retraction in: Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, Barry WT, Dressman HK, Ginsburg GS, Marcom KP, Garman KS, Lyman GH, Nevins JR, Potti A. JAMA. 2012 Feb 1;307(5):453.

PMID:
18387932
2.

Genomic predictors of outcome and treatment response in breast cancer.

Dunn L, Demichele A.

Mol Diagn Ther. 2009;13(2):73-90. doi: 10.2165/01250444-200913020-00002. Review.

PMID:
19537843
3.

Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.

Ward S, Scope A, Rafia R, Pandor A, Harnan S, Evans P, Wyld L.

Health Technol Assess. 2013 Oct;17(44):1-302. doi: 10.3310/hta17440. Review.

4.

Prognostic applications of gene expression signatures in breast cancer.

Normanno N, De Luca A, Carotenuto P, Lamura L, Oliva I, D'Alessio A.

Oncology. 2009;77 Suppl 1:2-8. doi: 10.1159/000258489. Epub 2010 Feb 2. Review.

PMID:
20130425
5.

Adjuvant chemotherapy--yes or no? Prognostic markers in early breast cancer.

Piccart-Gebhart MJ, Sotiriou C.

Ann Oncol. 2007 Dec;18 Suppl 12:xii2-7. doi: 10.1093/annonc/mdm532. Review.

PMID:
18083699
6.

Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer.

Swanton C, Szallasi Z, Brenton JD, Downward J.

Breast Cancer Res. 2008;10(5):214. doi: 10.1186/bcr2159. Epub 2008 Oct 31. Review.

7.

Tailoring Chemotherapy in Early-Stage Breast Cancer: Based on Tumor Biology or Tumor Burden?

Ribnikar D, Cardoso F.

Am Soc Clin Oncol Educ Book. 2016;35:e31-8. doi: 10.14694/EDBK_159077. Review.

8.

Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?

Bedard PL, Cardoso F.

Nat Rev Clin Oncol. 2011 May;8(5):272-9. doi: 10.1038/nrclinonc.2011.19. Epub 2011 Mar 1. Review.

PMID:
21364525
9.

The impact of expression profiling on prognostic and predictive testing in breast cancer.

Reis-Filho JS, Westbury C, Pierga JY.

J Clin Pathol. 2006 Mar;59(3):225-31. Review.

10.

DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design.

Andre F, Mazouni C, Hortobagyi GN, Pusztai L.

Biochim Biophys Acta. 2006 Dec;1766(2):197-204. Epub 2006 Aug 9. Review.

PMID:
16962247
11.

Clinical and therapeutic perspectives of gene expression profiling for breast cancer.

Chiuri VE, Leo G, Lorusso V.

Ann Oncol. 2007 Jun;18 Suppl 6:vi58-62. Review.

PMID:
17591834
12.

Derivation of cancer diagnostic and prognostic signatures from gene expression data.

Goodison S, Sun Y, Urquidi V.

Bioanalysis. 2010 May;2(5):855-62. doi: 10.4155/bio.10.35. Review.

13.

Challenges translating breast cancer gene signatures into the clinic.

Weigelt B, Pusztai L, Ashworth A, Reis-Filho JS.

Nat Rev Clin Oncol. 2011 Aug 30;9(1):58-64. doi: 10.1038/nrclinonc.2011.125. Review.

PMID:
21878891
14.

Gene expression profile assays as predictors of distant recurrence-free survival in early-stage breast cancer.

Kuderer NM, Lyman GH.

Cancer Invest. 2009 Nov;27(9):885-90. doi: 10.3109/07357900903275142. Review. No abstract available.

15.

Individualization of therapy using Mammaprint: from development to the MINDACT Trial.

Mook S, Van't Veer LJ, Rutgers EJ, Piccart-Gebhart MJ, Cardoso F.

Cancer Genomics Proteomics. 2007 May-Jun;4(3):147-55. Review.

16.

Treatment of pT1N0 breast cancer: multigene predictors to assess risk of relapse.

Fumagalli D, Sotiriou C.

Ann Oncol. 2010 Oct;21 Suppl 7:vii103-6. doi: 10.1093/annonc/mdq423. Review.

PMID:
20943601
17.

Breast cancer prognostication and prediction: are we making progress?

L√łnning PE.

Ann Oncol. 2007 Sep;18 Suppl 8:viii3-7. Review.

PMID:
17890212
18.

Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial.

Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van 't Veer LJ, Piccart M; TRANSBIG consortium.

Nat Clin Pract Oncol. 2006 Oct;3(10):540-51. Review.

PMID:
17019432
19.

What should physicians look for in evaluating prognostic gene-expression signatures?

Subramanian J, Simon R.

Nat Rev Clin Oncol. 2010 Jun;7(6):327-34. doi: 10.1038/nrclinonc.2010.60. Epub 2010 Apr 27. Review.

PMID:
20421890
20.

The microenvironment in breast cancer progression: biology and implications for treatment.

Place AE, Jin Huh S, Polyak K.

Breast Cancer Res. 2011;13(6):227. doi: 10.1186/bcr2912. Epub 2011 Nov 1. Review.

Supplemental Content

Support Center